BioTuesdays

Category - News

Histogenics
Markets

HCW cuts Histogenics PT to $2 from $3.50

H.C. Wainwright lowered its price target for Histogenics (NASDAQ:HSGX) to $2 from $3.50, but maintained its “buy” rating, after the company missed its primary endpoint in a Phase 3 study of NeoCart for knee cartilage...

September 5, 2018
Cyclacel Pharmaceuticals
Markets

Roth starts Cyclacel Pharma at buy; PT $8

Roth Capital Partners launched coverage of Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a “buy” rating and $8 price target. The stock closed at $1.57 on September 4. “We believe that Cyclacel, its clinical CDK inhibitor...

September 5, 2018
Vaccinex
Markets

Analysts start Vaccinex at buy; PTs $20 and $22

Analysts at BTIG and Ladenburg Thalmann initiated coverage of Vaccinex (NASDAQ:VCNX) with “buy” ratings and price targets of $20 and $22, respectively. The stock closed at $9.99 on August 31. Vaccinex, which went public...

September 4, 2018
Immune Design
Markets

HCW starts Immune Design at buy; PT $11

H.C. Wainwright initiated coverage of Immune Design (NASDAQ:IMDZ) with a “buy” rating and $11 price target. The stock closed at $3.45 on August 29. “Based on our broad and long-term coverage of cancer immunotherapy, we...

August 30, 2018
Sophiris Bio Logo
Markets

HCW ups Sophiris Bio PT to $10 from $4.30

H.C. Wainwright raised its price target for Sophiris Bio (NASDAQ:SPHS) to $10 from $4.30, citing autopsy results that found a patient deathin its Phase 2b trial for the treatment of localized prostate cancer was not...

August 30, 2018
Coherus BioSciences Logo
Markets

HCW starts Coherus BioSciences at buy; PT $28

H.C. Wainwright initiated coverage of Coherus BioSciences (NASDAQ:CHRS) with a “buy” rating and $28 price target. The stock closed at $19.75 on August 27. “We expect approval of UDENCYA, CHS-1701, in both the U.S. and...

August 28, 2018